FLF. Markus Leweke

F. Markus Leweke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


F. Markus Leweke has a total of 357 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of fluid endocannabinoid and sphingolipid biomarkers in schizophrenia. A machine learning approach toward clinical value

    by Anna E. Hoffmann, Michael Allwright, Boris Guennewig, Cathrin Rohleder, Beverly Jieu, Dagmar Koethe, Inga Dammann, Andrea Arroyo del Castillo, Juliane K. Mueller, Frank Enning, et al.

    Schizophrenia (SCZ) diagnosis relies on subjective clinical evaluation, with symptoms often overlapping between psychiatric conditions, hindering early intervention, and creating an urgent need for objective, accessible biomarkers. Lipids, especially endocannabinoid system (ECS) and sphingolipid metabolism members, are promising candidates given their implication in SCZ pathogenesis and measurability in accessible biofluids, with minimally invasive procedures. Our study conducted the first comprehensive crossover of endocannabinoids (eCBs) and sphingolipids in matched cerebrospinal fluid (CSF) and serum samples from antipsychotic-naïve SCZ patients (SCZ naïve , n = 49), antipsychotic-treated patients (SCZ treat , n = 56), and healthy volunteers (HVs, n = 51). The machine learning Integrated Disease Explanation and Risk Scoring (IDEARS) platform was applied to eCBs, N-acylethanolamines, ceramides, and sphingomyelins quantified using liquid chromatography-tandem mass spectrometry, identifying key discriminatory features across biofluids and conditions (CSF AUC: SCZ naïve = 0.87, SCZ treat = 0.94; serum AUC: SCZ naïve = 0.87, SCZ treat = 0.90). Anandamide emerged as the top CSF feature in SCZ naïve patients, showing significantly elevated levels (q = 0.010) compared to HVs. Notably, though not statistically significant under conventional statistics, IDEARS identified anandamide as a top ten serum feature. Additionally, elevated sphingadiene backbone (d18:2) sphingolipids were conserved between the CSF and serum of SCZ naïve (q < 0.05), highlighting their potential as peripheral surrogate markers. Treatment-specific ceramide patterns were also evident, with elevated C16-C18 and reduced long-chain (>C24) species potentially reflecting antipsychotic metabolic effects. Our results support the involvement of the ECS and sphingolipid imbalances in SCZ, highlighting the potential of machine learning for novel biomarker discovery, including stratification across biofluids, and therapeutic monitoring toward more objective psychiatric care.

  • Open Access

    Animal Models for Drug Discovery in Schizophrenia: A Critical View from a Clinical Perspective

    by Inga Dammann-Bawadkji, F. Markus Leweke, Cathrin Rohleder

    Schizophrenia is a complex neuropsychiatric disorder manifesting with diverse positive and negative symptoms as well as cognitive impairments. Current antipsychotics primarily address positive symptoms and frequently cause substantial side effects, highlighting the need for novel therapeutics targeting alternative pathomechanisms. Animal models are widely used to investigate schizophrenia's neurobiology and guide drug discovery, yet their clinical relevance for proof-of-concept (PoC) studies remains controversial. This Current Opinion critically examines the key limitations of animal models in schizophrenia research from a clinical perspective. The disorder’s multifaceted nature, involving genetic, environmental, and neurodevelopmental factors, makes accurate replication in animals challenging. Additionally, core human-specific symptoms, like hallucinations and thought disorders, cannot directly be modeled, although some underlying cross-species constructs can be operationalized. We argue that animal models are most informative when used to test specific, well-defined mechanistic hypotheses and when readouts are anchored to human-relevant biomarkers and neurophysiology, rather than interpreted as proxies for diagnostic categories. Accordingly, translational utility is not uniform: predictive performance depends on the induction paradigm, the construct validity of behavioral and neurophysiological readouts, and the clinical endpoint being modeled. We advocate for close collaboration between preclinical and clinical researchers to refine existing models, establish new and translationally relevant paradigms, and clearly define their interpretive scope. Integrating complementary advanced in vitro and in silico models may enhance mechanistic understanding and help prioritize hypotheses and candidates. Still, these approaches should be viewed as adjuncts, not superior replacements, because they cannot yet capture the circuit- and systems-level dynamics relevant to schizophrenia.


  • Open Access

    Novel youth mental health services in Australia: What differences are being reported about the clinical needs of those who attend and the outcomes achieved?

    by Ian B Hickie, Sebastian Rosenberg, Joanne S Carpenter, Jacob J Crouse, Blake Hamilton, Daniel Hermens, Adam Guastella, Markus Leweke, William Capon, Elizabeth M Scott, et al.

    Globally, youth mental health services are evolving, with Australia’s headspace services presented as a leading exemplar. headspace services were designed as enhanced primary care-based entities and were expected to collaborate with local acute, and specialist clinical and psychosocial services. The lack of large-scale health services trials necessitates understanding their impact through systematic monitoring and evaluation. This paper compares data from differing sources that describe the demographic and clinical features, and functional outcomes, of young people presenting to various headspace services. headspace National reports that care is provided largely to youth with transient distress, minimal clinical disorders, suicidality or comorbidities and limited functional impairment. Almost 50% of clients are reported to have no significant psychological symptoms or risk factors, and less than 30% to have a clinical disorder. Consequently, 36% receive only a single session of care and the median number of clinical sessions provided is three. By contrast, empirically derived estimates, utilising data from an academic centre and its affiliated centres, other independent agencies and more refined analyses of headspace national data variously portray 50–60% of youth as presenting with at least moderate clinical complexity (including at least 20% with high complexity), and with another 27% requiring active clinical intervention. Together, these data suggest approximately 75% of attendees require substantive clinical care. Clinical outcomes data from all sources indicate limited impacts on functional outcomes, with less than a third achieving significant improvement. These data support the original intent of headspace services to focus on equitable access to multidimensional and clinical assessment, evidence-based early interventions for early stages of major anxiety, mood or psychotic disorders. As demand for youth services continues to rise, there is an urgent need to reconfigure our national youth service networks to address the unmet clinical and psychosocial needs of youth presenting in the early stages of major mental disorders.


  • Open Access

    Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol

    by Beverly Jieu, Eliska B. Sykorova, Cathrin Rohleder, Elisabeth Marcolini, Anna E. Hoffmann, Dagmar Koethe, F. Markus Leweke, Timothy A. Couttas


  • Correction: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review

    by Inga Dammann, Cathrin Rohleder, F. Markus Leweke

    10.1055/a-2228-6118 In the above-mentioned article the COI has been updated. The correct COI is: FML is a shareholder of curantis UG (Ltd.) and received a research grant from Endosane Pharmaceuticals GmbH. Furthermore, FML is the co-founder and Medical Director of Endosane Pharmaceuticals GmbH, although this role operates through a consultancy agreement with curantis UG (Ltd.) as the primary affiliation. CR is a shareholder of lero bioscience UG (Ltd). CR and ID are currently employed by Endosane Pharmaceuticals GmbH. This was corrected in the online version on 09.02.2026. Article published online: 13 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review

    by Inga Dammann, Cathrin Rohleder, F. Markus Leweke

    The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited in most indications. This review comprises a comprehensive literature search to identify clinical studies on the effects of CBD in psychiatric conditions. The literature search included case studies, case reports, observational studies, and RCTs published in English before July 27, 2023, excluding studies involving nabiximols or cannabis extracts containing CBD and ∆9-tetrahydrocannabinol. Completed studies were considered, and all authors independently assessed relevant publications. Of the 150 articles identified, 54 publications were included, covering the effects of CBD on healthy subjects and various psychiatric conditions, such as schizophrenia, substance use disorders (SUDs), anxiety, post-traumatic stress disorder (PTSD), and autism spectrum disorders. No clinical studies have been published for other potential indications, such as alcohol use disorder, borderline personality disorder, depression, dementia, and attention-deficit/hyperactivity disorder. This critical review highlights that CBD can potentially ameliorate certain psychiatric conditions, including schizophrenia, SUDs, and PTSD. However, more controlled studies and clinical trials, particularly investigating the mid- to long-term use of CBD, are required to conclusively establish its efficacy and safety in treating these conditions. The complex effects of CBD on neural activity patterns, likely by impacting the endocannabinoid system, warrant further research to reveal its therapeutic potential in psychiatry. † Co-senior authorship: Cathrin Rohleder, F. Markus Leweke Received: 25 August 2023 Received: 22 November 2023 Accepted: 04 December 2023 Article published online: 24 January 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers

    by Timothy A Couttas, Carola Boost, Franziska Pahlisch, Eliska B Sykorova, Juliane K Mueller, Beverly Jieu, Judith E Leweke, Inga Dammann, Anna E Hoffmann, Martin Loeffler, et al.

    Background: The mental health benefits of cannabidiol (CBD) are promising but can be inconsistent, in part due to challenges in defining an individual’s effective dosage. In schizophrenia, alterations in anandamide (AEA) concentrations, an endocannabinoid (eCB) agonist of the eCB system, reflect positively on treatment with CBD. Here, we expanded this assessment to include eCBs alongside AEA congeners, comparing phytocannabinoids and dosage in a clinical setting. Methods: Liquid chromatography-tandem mass spectrometry quantified changes in serum levels of AEA, 2-arachidonoylglycerol (2-AG), alongside AEA-related compounds oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), which were attained from two independent, parallel-designed, clinical trials investigating single, oral CBD (600 or 800 mg), delta-9-tetrahydrocannabinol (Δ9-THC, 10 or 20 mg) and combination administration (CBD|800 mg+Δ9-THC|20 mg) in healthy volunteers (HVs, n=75). Concentrations were measured at baseline (t=0), 65 and 160 min post administration. Results: CBD-led increases in AEA (1.6-fold), OEA and PEA (1.4-fold) were observed following a single 800 mg (pcorr9-THC at 10 mg (−1.3-fold) and 20 mg (−1.4-fold) but restored to baseline levels by 160 min. CBD+Δ9-THC yielded the highest increases in AEA (2.1-fold), OEA (1.9-fold) and PEA (1.8-fold) without reaching a maximal response. Conclusion: CBD-administered effects towards AEA, OEA and PEA are consistent with phase II trials reporting clinical improvement for acute schizophrenia (CBD≥800 mg). Including Δ9-THC appears to enhance the CBD-induced response towards AEA and its congeners. Our results warrant further investigations into the potential of these lipid-derived mediators as metabolic measures for CBD dose prescription and co-cannabinoid administration.


  • Open Access

    Plasma endocannabinoids in cocaine dependence and their relation to cerebral metabotropic glutamate receptor 5 density

    by Sara L. Kroll, Lea M. Hulka, Ann-Kathrin Kexel, Matthias Vonmoos, Katrin H. Preller, Valerie Treyer, Simon M. Ametamey, Markus R. Baumgartner, Carola Boost, Franziska Pahlisch, et al.

    Animal models indicate that the endocannabinoid system (ECS) plays a modulatory role in stress and reward processing, both crucially impaired in addictive disorders. Preclinical findings showed endocannabinoid-modulated synaptic plasticity in reward brain networks linked to the metabotropic-glutamate-5 receptor (mGluR5), contributing to drug-reinforcing effects and drug-seeking behavior. Although animal models postulate a link between ECS and cocaine addiction, human translational studies are lacking. Here, we tested previous preclinical findings by investigating plasma endocannabinoids (eCBs) anandamide (AEA), 2-arachidonoylglycerol (2-AG), and the related N-acylethanolamines (NAEs) palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), including their interaction with cerebral mGluR5, in chronic cocaine users (CU). We compared basal plasma concentrations between chronic CU (N = 103; 69 recreational CU and 34 dependent CU) and stimulant-naïve healthy controls (N = 92). Follow-up basal eCB/NAE plasma levels after 12 months were used for reliability and stability check (CU:N = 33; controls:N = 43). In an additional analysis using11C-ABP688 positron emission tomography (PET) in a male subsample (CU:N = 18; controls:N = 16), we investigated the relationships between eCBs/NAEs and mGluR5 density in the brain. We found higher 2-AG plasma levels in dependent CU compared to controls and recreational CU. 2-AG levels were stable over time across all groups. In the PET-subsample, a positive association between 2-AG and mGluR5 brain density only in CU was found. Our results corroborate animal findings suggesting an alteration of the ECS in cocaine dependence and an association between peripheral 2-AG levels and cerebral mGluR5 in humans. Therefore, the ECS might be a promising pharmaco-therapeutic target for novel treatments of cocaine dependence.


  • Open Access

    Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and N -Acylethanolamines by Liquid Chromatography–Tandem Mass Spectrometry

    by Timothy A. Couttas, Carola Boost, Franziska Pahlisch, Eliska B. Sykorova, Judith E. Leweke, Dagmar Koethe, Heike Endepols, Cathrin Rohleder, F. Markus Leweke

    Introduction: The primary compounds of Cannabis sativa , delta-9-tetrahydrocannabinol (Δ 9 -THC) and cannabidiol (CBD), inflict a direct influence on the endocannabinoid system-a complex lipid signaling network with a central role in neurotransmission and control of inhibitory and excitatory synapses. These phytocannabinoids often interact with endogenously produced endocannabinoids (eCBs), as well as their structurally related N -acylethanolamines (NAEs), to drive neurobiological, nociceptive, and inflammatory responses. Identifying and quantifying changes in these lipid neuromodulators can be challenging owing to their low abundance in complex matrices. Materials and Methods: This article describes a robust liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for the extraction and quantification of the eCBs anandamide and 2-arachidonoylglycerol, along with their congener NAEs oleoylethanolamine and palmitoylethanolamine, and phytocannabinoids CBD, Δ 9 -THC, and 11-Nor-9-carboxy-Δ 9 -tetrahydrocannabinol, a major metabolite of Δ 9 -THC. Our method was applied to explore pharmacokinetic and pharmacodynamic effects from intraperitoneal injections of Δ 9 -THC and CBD on circulating levels of eCBs and NAEs in rodent serum. Results: Detection limits ranged from low nanomolar to picomolar in concentration for eCBs (0.012–0.24 pmol/mL), NAEs (0.059 pmol/mL), and phytocannabinoids (0.24–0.73 pmol/mL). Our method displayed good linearity for calibration curves of all analytes ( R 2 >0.99) as well as acceptable accuracy and precision, with quality controls not deviating >15% from their nominal value. Our LC-MS/MS method reliably identified changes to these endogenous lipid mediators that followed a causal relationship, which was dependent on both the type of phytocannabinoid administered and its pharmaceutical preparation. Conclusion: We present a rapid and reliable method for the simultaneous quantification of phytocannabinoids, eCBs, and NAEs in serum using LC-MS/MS. The accuracy and sensitivity of our assay infer it can routinely monitor endogenous levels of these lipid neuromodulators in serum and their response to external stimuli, including cannabimimetic agents.


  • Open Access

    Plasma endocannabinoids in cocaine dependence and their interaction with cocaine craving and metabotropic glutamate receptor 5 density in the human brain

    by Sara L. Kroll, Lea M. Hulka, Ann-Kathrin Kexel, Matthias Vonmoos, Katrin H. Preller, Valerie Treyer, Simon M. Ametamey, Markus R. Baumgartner, Carola Boost, Franziska Pahlisch, et al.

    Animal models indicate that the endocannabinoid system (ECS) plays a modulatory role in stress and reward processing, both crucially impaired in addictive disorders. Preclinical findings showed endocannabinoid-modulated synaptic plasticity in reward brain networks linked to the metabotropic-glutamate-5 receptor (mGluR5), contributing to drug-reinforcing effects and drug-seeking behavior. Although animal models postulate a link between ECS and cocaine addiction, human translational studies are lacking. Here, we tested previous preclinical findings by investigating plasma endocannabinoids (eCBs) anandamide (AEA), 2-arachidonoylglycerol (2-AG), and the related N-acylethanolamines (NAEs) palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), including their interaction with cerebral mGluR5, in chronic cocaine users (CU). We compared basal plasma concentrations between chronic CU (N=103; 69 recreational CU and 34 dependent CU) and stimulant-naïve healthy controls (N=92). Follow-up basal eCB/NAE plasma levels after 12 months were used for reliability and stability check (CU: N=33; controls: N=43). In an additional analysis using 11 C-ABP688 positron emission tomography (PET) in a male subsample (CU: N=18; controls: N=16), we investigated the relationships between eCBs/NAEs and mGluR5 density in the brain. We found higher 2-AG plasma levels in dependent CU compared to controls and recreational CU. 2-AG levels were stable over time across all groups. In the PET-subsample, a positive association between 2-AG and mGluR5 brain density only in CU was found. Our results corroborate animal findings suggesting an alteration of the ECS in cocaine dependence and an association between peripheral 2-AG levels and cerebral mGluR5 in humans. Therefore, the ECS might be a promising pharmaco-therapeutic target for novel treatments of cocaine dependence.